Systolic Heart Failure – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Systolic Heart Failure – Drugs In Development, 2024 report and make more profitable business decisions.
Systolic heart failure is a cardiovascular disorder marked by specific features, including the enlargement of the heart’s ventricles, resulting in reduced ejection fraction, a measure of the heart’s pumping efficiency. This condition can manifest as either a chronic, long-term issue or an acute, sudden onset event. However, in both forms, a critical factor contributing to the progression of systolic heart failure is left ventricular remodeling. This process involves structural and functional changes in the left ventricle of the heart, ultimately impacting its ability to pump blood effectively. These alterations in heart shape and function lead to a vicious cycle of deteriorating cardiac performance, making left ventricular remodeling a central concern in the management and understanding of systolic heart failure.
The Systolic Heart Failure drugs in development market research report provide comprehensive information on the therapeutics under development for Systolic Heart Failure, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Systolic Heart Failure and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Systolic Heart Failure | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 28 molecules, with 28 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Systolic Heart Failure therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Systolic Heart Failure pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Systolic Heart Failure treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AnaCardio ABBayer AG
BioCardia Inc
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Cardurion Pharmaceuticals LLC
Cytokinetics Inc
DiNAQOR AG
Eris Lifesciences Ltd
Heartseed Inc
Innolife Co Ltd
Intra-Cellular Therapies Inc
Ionis Pharmaceuticals Inc
Japan Tobacco Inc
Ji Xing Pharmaceuticals Ltd
Johnson & Johnson
Keros Therapeutics Inc
Novartis AG
Novo Nordisk AS
Olatec Therapeutics LLC
Remd Biotherapeutics Inc
Salubris Biotherapeutics Inc
Sarfez Pharmaceuticals Inc
Shenzhen Salubris Pharmaceuticals Co Ltd
Tenaya Therapeutics Inc
Zensun (Shanghai) Sci & Tech Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Systolic Heart Failure reports